HR+/HER2- Advanced Breast Cancer and Endocrine Resistance

NCT03322215 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

42

Enrollment

OTHER

Sponsor class

Stopped Slow accrual

Conditions

Breast Cancer Metastatic

Interventions

DRUG: Palbociclib
DRUG: Fulvestrant
DRUG: Capecitabine

Sponsor

Theodoros Foukakis